No Detail Found!

Outcomes of Chemotherapy plus Cetuximab as First-line Treatment in Patients with Metastatic, Recurrent, Unresectable Head and Neck Cancers: Real-life Data

Author(s)
Dogan Yazilitas Department of Medical Oncology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital,Ankara,Turkiye
Hayriye Sahinli Department of Medical Oncology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital,Ankara,Turkiye
Guleser Saylam Department of Otolaryngology, Head and Neck Surgery, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital,Ankara,Turkiye
Goksen Inanc Imamoglu Department of Medical Oncology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital,Ankara,Turkiye
Mehmet Hakan Korkmaz Department of Medical Oncology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital,Ankara,Turkiye
Omer Bayir Department of Medical Oncology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital,Ankara,Turkiye
Abstract
Objective: To examine the treatment outcomes of the EXTREME regimen as the rst-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck. Study Design: Observational study. Place and Duration of the Study: Department of Medical Oncology, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Turkiye, between January 2014 and December 2021. Methodology: A total of 60 patients with recurrent/metastatic head and neck cancers were treated with EXTREME regimen. Survival curves were estimated using the Kaplan-Meier method. Cox proportional hazards regression models were used to determine the factors associated with progression-free survival (PFS) and overall survival (OS). Results: Patients receiving cetuximab in combination with chemotherapy for metastatic or unresectable disease were obtained from patient les and electronic medical records. Majority of patients were male (78.3%). The median PFS of patients was 7 months. The median survival of the patients was 9.06 months. During follow-up, 55 patients (91.7%) relapsed, and 51 patients (85%) died. The median survival of patients with eastern cooperative oncology group (ECOG) performance status 0, 1, and 2 was 16, 9, and 4 months, respectively. And the survival of patients was found signi cantly lower with lower ECOG performance scores. Conclusion: OS was determined as 9.06 months. ECOG performance score had an important e ect on the survival.
Publication Details
Page(s) 469-473
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 33, Issue: 4, Year: 2023

Request the full text from PASTIC

Keywords
chemotherapy, Head and neck cancer, Cetuximab
0

Citations

0

Downloads

70

Views